Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / European Union / Regeneron Pharmaceuticals

European Union & Regeneron Pharmaceuticals

2 shared events · Importance 3 · Last updated Jun 04, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
0
Business
Dupixent EU Recommendation, US Approval
Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.
Feb 24, 2026 · 8 articles
0
Business
Dupixent Approved for Pediatric CSU in EU
Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
NEWSDESK
Explore this relationship live

Track how European Union and Regeneron Pharmaceuticals interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.